New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
MetadataShow full item record
Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach. © 2013 Author(s).
Showing items related by title, author, creator and subject.
Pirillo, A.; Norata, Giuseppe; Catapano, A. (2017)Purpose of review: Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in particular, high levels of low-density lipoprotein cholesterol (LDL-C) have been associated to a higher cardiovascular risk. ...
Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: The atherosclerosis risk in communities studyLopez, F.; Agarwal, S.; MacLehose, R.; Soliman, E.; Sharrett, A.; Huxley, Rachel; Konety, S.; Ballantyne, C.; Alonso, A. (2012)Background-Several cardiovascular risk factors have been associated with the risk of atrial fibrillation (AF). Limited and inconsistent evidence exists on the association of blood lipid levels and lipid-lowering medication ...
IDOL N342S variant, atherosclerosis progression and cardiovascular disorders in the italian general populationDhyani, A.; Tibolla, G.; Baragetti, A.; Garlaschelli, K.; Pellegatta, F.; Grigore, L.; Norata, Giuseppe; Catapano, A. (2015)Inducible degrader of the low density lipoprotein receptor (IDOL), is an E3 ubiquitin ligase that negatively modulates low density lipoprotein receptor (LDL-R) expression. Genome-wide association studies (GWAS) indicated ...